

IN THE CLAIMS:

Amendments to the Claims

Claims 1 – 5 (canceled).

Claim 6 (withdrawn): The method according to claim 4, wherein the TNF $\alpha$  antagonist is p55TNFR:Fc.

Claims 7 - 11 (canceled).

Claim 12 (withdrawn): The method according to claim 10, wherein the TNF $\alpha$  antagonist is p55TNFR:Fc.

Claims 13 – 16 (canceled).

Claim 17 (withdrawn): The method according to claim 15, wherein the TNF $\alpha$  antagonist is p55TNFR:Fc.

Claim 18 (new): A method of treating or inhibiting cellular injury or cell death during a procedure which involves ischemic events followed by reperfusion in a mammal in need thereof, which comprises providing an effective amount of a TNF $\alpha$  antagonist to said mammal prior to or during said procedure.

Claim 19 (new): The method according to claim 18, wherein said procedure is transplant surgery, angioplasty, coronary stent placement, thrombolytic therapy, heart valve replacement or bypass surgery.

Claim 20 (new): The method according to claim 18 where the TNF $\alpha$  antagonist is a TNF receptor/immunoglobulin fusion protein.

Claim 21 (new): The method according to claim 20, wherein the TNF $\alpha$  antagonist comprises a fragment of TNFR and a portion or the entire constant region of a human immunoglobulin heavy chain.

Claim 22 (new): The method of claim 21, wherein the TNF $\alpha$  antagonist is etanercept.

Claim 23 (new): The method of claim 21, wherein the TNF $\alpha$  antagonist is p55TNFR:Fc.